233 related articles for article (PubMed ID: 30033299)
21. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
[No Abstract] [Full Text] [Related]
24. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers.
Kutty RV; Feng SS
Biomaterials; 2013 Dec; 34(38):10160-71. PubMed ID: 24090836
[TBL] [Abstract][Full Text] [Related]
26. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
[TBL] [Abstract][Full Text] [Related]
27. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
28. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
29. [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.
Baptista Moreno Martin AC; Tomasin R; Luna-Dulcey L; Graminha AE; Araújo Naves M; Teles RHG; da Silva VD; da Silva JA; Vieira PC; Annabi B; Cominetti MR
Cell Oncol (Dordr); 2020 Oct; 43(5):915-929. PubMed ID: 32761561
[TBL] [Abstract][Full Text] [Related]
30. Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species.
Roy A; Ahir M; Bhattacharya S; Parida PK; Adhikary A; Jana K; Ray M
Mol Carcinog; 2017 Sep; 56(9):2086-2103. PubMed ID: 28418078
[TBL] [Abstract][Full Text] [Related]
31. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
32. Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells.
Pindiprolu SKSS; Chintamaneni PK; Krishnamurthy PT; Ratna Sree Ganapathineedi K
Drug Dev Ind Pharm; 2019 Feb; 45(2):304-313. PubMed ID: 30348020
[TBL] [Abstract][Full Text] [Related]
33. Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms.
Kang J; Park JH; Lee HJ; Jo U; Park JK; Seo JH; Kim YH; Kim I; Park KH
Cancer Res Treat; 2016 Apr; 48(2):715-26. PubMed ID: 26511813
[TBL] [Abstract][Full Text] [Related]
34. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.
Feng Z; Xia Y; Gao T; Xu F; Lei Q; Peng C; Yang Y; Xue Q; Hu X; Wang Q; Wang R; Ran Z; Zeng Z; Yang N; Xie Z; Yu L
Cell Death Dis; 2018 Sep; 9(10):1006. PubMed ID: 30258182
[TBL] [Abstract][Full Text] [Related]
35. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
36. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol loaded oxidized mesoporous carbon nanoparticles: A promising tool to treat triple negative breast cancer.
Fan C; Kong F; Shetti D; Zhang B; Yang Y; Wei K
Biochem Biophys Res Commun; 2019 Nov; 519(2):378-384. PubMed ID: 31519327
[TBL] [Abstract][Full Text] [Related]
38. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway.
Martins S; Costa-Lima S; Carneiro T; Cordeiro-da-Silva A; Souto EB; Ferreira DC
Int J Pharm; 2012 Jul; 430(1-2):216-27. PubMed ID: 22465548
[TBL] [Abstract][Full Text] [Related]
39. PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells).
Meena R; Kumar S; Kumar R; Gaharwar US; Rajamani P
Biomed Pharmacother; 2017 Oct; 94():944-954. PubMed ID: 28810532
[TBL] [Abstract][Full Text] [Related]
40. Aurovertin B exerts potent antitumor activity against triple-negative breast cancer
Wu R; Yang X; Zhou Q; Yu W; Li M; Wo J; Shan W; Zhao H; Chen Y; Zhan Z
Pharmazie; 2020 Jun; 75(6):261-265. PubMed ID: 32539922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
